利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

68 条记录 (耗时 0.042 秒)

    Oil-in-water method for making polymeric implants containing a hypotensive lipid
    1.
    发明授权
    Oil-in-water method for making polymeric implants containing a hypotensive lipid 有权
    用于制造含有低血压脂质的聚合物植入物的水包油法

    公开(公告)号：US08722097B2

    公开(公告)日：2014-05-13

    申请号：US11371118

    申请日：2006-03-08

    申请人： James Chang ,  Patrick Hughes ,  Chin-Ming Chang

    发明人： James Chang ,  Patrick Hughes ,  Chin-Ming Chang

    IPC分类号： A61K9/50 ,  B01J13/02 ,  B01J13/04

    CPC分类号： A61K31/5575 ,  A61K9/0048 ,  A61K9/0051 ,  A61K9/107 ,  A61K9/1075 ,  A61K9/146 ,  A61K9/1647 ,  A61K9/1694 ,  A61K31/165 ,  A61K47/34 ,  B01J13/04 ,  B01J13/06

    摘要： Biocompatible microparticles include an ophthalmically active cyclic lipid component and a biodegradable polymer that is effective, when placed into the subconjunctival space, in facilitating release of the cyclic lipid component into the anterior and posterior segments of an eye for an extended period of time. The cyclic lipid component can be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. Or, the cyclic lipid component can be encapsulated by the polymeric component. The present microparticles include oil-in-water emulsified microparticles. The subconjunctivally administered microparticles can be used to treat or to reduce at least one symptom of an ocular condition, such as glaucoma or age related macular degeneration.

    摘要翻译： 生物相容的微粒包括眼科活性的环状脂质组分和可生物降解的聚合物，当放置在结膜下空间中时，有效地促进环状脂质成分延长眼睛部分的时间。 环状脂质组分可与可生物降解的聚合物基质相结合，例如两种可生物降解聚合物的基质。 或者，环状脂质组分可以被聚合物组分包封。 本发明的微粒包括水包油乳化微粒。 结膜下施用的微粒可用于治疗或减少眼部疾病如青光眼或年龄相关性黄斑变性的至少一种症状。

    Method and compositions for the intravenous administration of compounds related to proton pump inhibitors
    4.
    发明申请
    Method and compositions for the intravenous administration of compounds related to proton pump inhibitors 审中-公开
    用于静脉内施用与质子泵抑制剂相关的化合物的方法和组合物

    公开(公告)号：US20070161679A1

    公开(公告)日：2007-07-12

    申请号：US10597804

    申请日：2005-01-14

    申请人： Patrick Hughes

    发明人： Patrick Hughes

    IPC分类号： A61K31/4439

    CPC分类号： A61K9/0014 ,  A61K31/4439 ,  A61K45/06 ,  A61K47/02 ,  A61K47/12 ,  A61K47/54 ,  A61K2300/00

    摘要： Disclosed herein are liquid compositions comprising a therapeutically effective concentration of a prodrug of a sulfonyl-containing proton pump inhibitor, wherein said compositions have a pH of from 3 to 7.3. Solid compositions related thereto are also disclosed. Methods of delivering a proton pump related thereto are also disclosed. Compositions comprising a second therapeutically active agent are also disclosed herein.

    摘要翻译： 本文公开了包含治疗有效浓度的含磺酰基的质子泵抑制剂的前药的液体组合物，其中所述组合物的pH为3至7.3。 还公开了与其相关的固体组合物。 还公开了与其相关的输送质子泵的方法。 本文还公开了包含第二治疗活性剂的组合物。

    Sustained release intraocular drug delivery systems
    6.
    发明申请
    Sustained release intraocular drug delivery systems 审中-公开
    持续释放眼内药物递送系统

    公开(公告)号：US20060182783A1

    公开(公告)日：2006-08-17

    申请号：US11370301

    申请日：2006-03-08

    申请人： Patrick Hughes ,  Gerald Devries ,  Jeffrey Edelman ,  Wendy Blanda ,  Lon Spada ,  Robert Lyons

    发明人： Patrick Hughes ,  Gerald Devries ,  Jeffrey Edelman ,  Wendy Blanda ,  Lon Spada ,  Robert Lyons

    IPC分类号： A61K48/00 ,  A61F2/00

    CPC分类号： A61K9/0051 ,  A61F9/0008 ,  A61F9/0017 ,  A61K9/1647 ,  A61K31/724 ,  A61K47/34 ,  A61K47/40 ,  A61K48/0041

    摘要： Biocompatible intraocular drug delivery systems include a anti-angiogenic macromolecular therapeutic agent and a polymeric component in the form of an implant, a microparticle, a plurality of implants or microparticles, and combinations thereof. The therapeutic agent is released in a biologically active form, for example, the therapeutic agent may retain its three dimensional structure when released into an eye of a patient, or the therapeutic agent may have an altered three dimensional structure but retain its therapeutic activity. The therapeutic agent contains a component selected from the group consisting of anti-angiogenesis peptides and nucleic acid agents. The implants may be placed in an eye to treat or reduce the occurrence of one or more ocular conditions, such as retinal damage, including glaucoma and proliferative vitreoretinopathy among others.

    摘要翻译： 生物相容性眼内药物递送系统包括抗血管生成大分子治疗剂和植入物，微粒，多种植入物或微粒形式的聚合物组分及其组合。 治疗剂以生物活性形式释放，例如，当释放到患者的眼睛中时，治疗剂可以保持其三维结构，或者治疗剂可以具有改变的三维结构，但保持其治疗活性。 治疗剂含有选自抗血管生成肽和核酸试剂的组分。 植入物可以放置在眼睛中以治疗或减少一种或多种眼部病症的发生，例如视网膜损伤，包括青光眼和增生性玻璃体视网膜病变等。

    Methods for treating ocular conditions with cyclic lipid contraining microparticles
    7.
    发明申请
    Methods for treating ocular conditions with cyclic lipid contraining microparticles 审中-公开
    用抑制微粒的环状脂质治疗眼部病症的方法

    公开(公告)号：US20060182781A1

    公开(公告)日：2006-08-17

    申请号：US11368845

    申请日：2006-03-06

    申请人： Patrick Hughes ,  Joan-En Chang-Lin ,  Devin Welty

    发明人： Patrick Hughes ,  Joan-En Chang-Lin ,  Devin Welty

    IPC分类号： A61F2/00

    CPC分类号： A61F9/00781 ,  A61F2210/0004 ,  A61K9/0051 ,  A61K9/1647 ,  A61K31/00

    摘要： Biocompatible microparticles include a ophthalmically active cyclic lipid component and a biodegradable polymer that is effective, when placed into the subconjunctival space, in facilitating release of the cyclic lipid component into the anterior and posterior segments of an eye for an extended period of time. The cyclic lipid component can be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. Or, the cyclic lipid component can be encapsulated by the polymeric component. The present microparticles include oil-in-oil emulsified microparticles. The subconjunctivally administered microparticles can be used to treat or to reduce at least one symptom of an ocular condition, such as glaucoma or age related macular degeneration.

    摘要翻译： 生物相容的微粒包括眼科活性的环状脂质组分和可生物降解的聚合物，当放置在结膜下空间中时，有利于将脂质组分释放到眼睛的前部和后部段中延长的时间。 环状脂质组分可与可生物降解的聚合物基质相结合，例如两种可生物降解聚合物的基质。 或者，环状脂质组分可以被聚合物组分包封。 本发明的微粒包括油包水乳化微粒。 结膜下施用的微粒可用于治疗或减少眼部疾病如青光眼或年龄相关性黄斑变性的至少一种症状。

    Macromolecule-containing sustained release intraocular implants and related methods
    8.
    发明申请
    Macromolecule-containing sustained release intraocular implants and related methods 审中-公开
    含大分子的持续释放眼内植入物及相关方法

    公开(公告)号：US20050281861A1

    公开(公告)日：2005-12-22

    申请号：US11116698

    申请日：2005-04-27

    申请人： Patrick Hughes ,  Tom Malone ,  Gerald Devries ,  Jeffrey Edelman ,  Wendy Blanda ,  Lon Spada ,  Peter Baciu ,  Scott Whitcup

    发明人： Patrick Hughes ,  Tom Malone ,  Gerald Devries ,  Jeffrey Edelman ,  Wendy Blanda ,  Lon Spada ,  Peter Baciu ,  Scott Whitcup

    IPC分类号： A61F2/00 ,  A61F9/00 ,  A61K9/00 ,  A61K9/16 ,  A61K31/724 ,  A61K39/395 ,  A61K47/34 ,  A61K47/40 ,  A61K47/48 ,  A61K48/00

    CPC分类号： A61K9/0051 ,  A61F9/0008 ,  A61F9/0017 ,  A61K9/1647 ,  A61K31/724 ,  A61K47/34 ,  A61K47/40

    摘要： Biocompatible intraocular drug delivery systems include a non-neurotoxic macromolecule therapeutic agent and a polymeric component in the form of an implant, a microparticle, a plurality of implants or microparticles, and combinations thereof. The macromolecule therapeutic agent is released in a biologically active form, for example, the therapeutic agent may retain its three dimensional structure when released into an eye of a patient, or the therapeutic agent may have an altered three dimensional structure but retain its therapeutic activity. The therapeutic agent may be selected from the group consisting of anti-angiogenesis agents, ocular hemorrhage treatment agents, non-steroidal anti-inflammatory agents, growth factor inhibitors (such as VEGF inhibitors), growth factors, cytokines, antibodies, oligonucleotide aptamers, siRNA molecules and antibiotics. The implants may be placed in an eye to treat or reduce the occurrence of one or more ocular conditions, such as retinal damage, including glaucoma and proliferative vitreoretinopathy among others.

    摘要翻译： 生物相容性眼内药物递送系统包括非神经毒性大分子治疗剂和植入物，微粒，多种植入物或微粒形式的聚合物组分及其组合。 大分子治疗剂以生物活性形式释放，例如，当释放到患者的眼睛中时，治疗剂可保留其三维结构，或者治疗剂可具有改变的三维结构，但保持其治疗活性。 治疗剂可以选自抗血管生成剂，眼出血治疗剂，非甾体抗炎剂，生长因子抑制剂（例如VEGF抑制剂），生长因子，细胞因子，抗体，寡核苷酸适体，siRNA 分子和抗生素。 植入物可以放置在眼睛中以治疗或减少一种或多种眼部病症的发生，例如视网膜损伤，包括青光眼和增生性玻璃体视网膜病变等。

    Sustained release intraocular implants and methods for preventing retinal dysfunction
    9.
    发明申请
    Sustained release intraocular implants and methods for preventing retinal dysfunction 审中-公开
    持续释放眼内植入物和预防视网膜功能障碍的方法

    公开(公告)号：US20050244506A1

    公开(公告)日：2005-11-03

    申请号：US11118519

    申请日：2005-04-29

    申请人： James Burke ,  Patrick Hughes ,  Werhner Orilla ,  Ton Lin ,  Maria Escobar ,  Glenn Huang ,  Kai-Ming Zhang ,  Larry Wheeler ,  Rosy Donn

    发明人： James Burke ,  Patrick Hughes ,  Werhner Orilla ,  Ton Lin ,  Maria Escobar ,  Glenn Huang ,  Kai-Ming Zhang ,  Larry Wheeler ,  Rosy Donn

    IPC分类号： A61F2/02 ,  A61K9/00 ,  A61K9/14 ,  A61K31/498

    CPC分类号： A61K31/498 ,  A61K9/0051 ,  A61K47/34

    摘要： Biocompatible intraocular microspheres and implants include an alpha-2 adrenergic receptor agonist and a polymer associated with the alpha-2 adrenergic receptor agonist to facilitate release of the alpha-2 adrenergic receptor agonist into an eye for an extended period of time. The alpha-2 adrenergic receptor agonist may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants may be placed in an eye to treat or to prevent the occurrence of one or more ocular conditions, to reduce one or more symptoms of an ocular condition, such as an ocular neurosensory disorder and the like, to enhance normal retinal function and/or to lower intraocular pressure.

    摘要翻译： 生物相容的眼内微球和植入物包括α-2肾上腺素能受体激动剂和与α-2肾上腺素能受体激动剂相关的聚合物，以促进α-2肾上腺素能受体激动剂延长一段时间的眼睛释放。 α-2肾上腺素能受体激动剂可以与可生物降解的聚合物基质例如两种可生物降解的聚合物的基质相关联。 植入物可以放置在眼睛中以治疗或防止一种或多种眼部病症的发生，以减少眼部疾病如眼部神经感觉障碍等的一种或多种症状，以增强正常的视网膜功能和/ 或降低眼内压。